Vaxxinity
Update in progressVAXX (OTC Markets OTCPK)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Vaxxinity, Inc. is a Merritt Island, Florida-based biotechnology company developing therapies for neurology, cardiovascular health, and Covid-19. Its pipeline includes UB-311 (phase 2) targeting toxic amyloid-beta for Alzheimer’s, UB-312 (phase 1) targeting toxic alpha-synuclein for Parkinson’s and other synucleinopathies, and VXX-301 (preclinical) an anti-tau candidate. It also advances VXX-401 (phase 1) to lower LDL-C by targeting PCSK9, UB-313 for migraines, and UB-612 for SARS-CoV-2 in phase 3.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.15
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketOTC Markets OTCPK (PNK)
- LocationUnited States
- CEOMs. Mei Mei Hu J.D.
- Founded2021
- Employees57
- Websitewww.vaxxinity.com
Identifiers
- ISINUS92244V1044
- FIGIBBG00ZWVMKJ9
- CUSIP92244V104
- CIK0001851657